Translate Bio Inc (NASDAQ:TBIO) major shareholder Baupost Group Llc/Ma purchased 500,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were purchased at an average cost of $22.00 per share, for a total transaction of $11,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of TBIO stock opened at $17.92 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.12 and a quick ratio of 4.12. The company has a market capitalization of $1.14 billion, a P/E ratio of -10.54 and a beta of 0.53. The company’s 50-day simple moving average is $17.85 and its two-hundred day simple moving average is $11.26. Translate Bio Inc has a one year low of $6.80 and a one year high of $28.09.
Translate Bio (NASDAQ:TBIO) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.20. The firm had revenue of $4.65 million for the quarter, compared to the consensus estimate of $2.23 million. Translate Bio had a negative net margin of 859.22% and a negative return on equity of 63.61%. On average, research analysts expect that Translate Bio Inc will post -1.57 EPS for the current fiscal year.
A number of brokerages recently issued reports on TBIO. Zacks Investment Research upgraded Translate Bio from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Friday, June 19th. Citigroup lifted their price objective on Translate Bio from $17.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. Jefferies Financial Group raised their target price on Translate Bio from $17.00 to $29.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. ValuEngine cut Translate Bio from a “buy” rating to a “hold” rating in a research note on Monday, June 1st. Finally, Roth Capital raised their target price on Translate Bio from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $29.00.
About Translate Bio
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.